Navigation Links
Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
Date:8/19/2007

ong clinical rationale to pursue development of PDX in this setting," said Dr. Horwitz.

Information regarding this study is available at http://www.allos.com or the U.S. government's clinical trials database at http://www.clinicaltrials.gov.

About Cutaneous T-cell Lymphoma

The cutaneous T-cells lymphomas are comprised of a number of non-Hodgkins T-cell lymphomas, including mycosis fungoides and Sezary syndrome, which have their primary manifestations in the skin. According to the Lymphoma Research Foundation, CTCL comprises about 2% to 3% of the estimated 63,000 new cases of non-Hodgkin's lymphoma diagnosed annually.

About PDX (pralatrexate)

PDX is a novel, small molecule chemotherapeutic agent that inhibits dihydrofolate reductase, or DHFR, a folic acid (folate)-dependent enzyme involved in the building of nucleic acid, or DNA, and other processes. PDX was rationally designed for efficient transport into tumor cells via the reduced folate carrier, or RFC-1, and effective intracellular drug retention. We believe these biochemical features, together with preclinical and clinical data in a variety of tumors, suggest that PDX may have a favorable safety and efficacy profile relative to methotrexate and certain other DHFR inhibitors.

About Allos Therapeutics, Inc.

Allos Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer. The company's lead product candidate, PDX (pralatrexate), is a novel antifolate currently under evaluation in a pivotal Phase 2 trial in patients with relapsed or refractory peripheral T-cell lymphoma. The company is also investigating PDX in patients with non-small cell lung cancer and a range of other lymphoma sub-types. The Company's other product candidate is RH1, a targeted chemotherapeutic agent, for w
'/>"/>

SOURCE Allos Therapeutics, Inc.

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
2. Allos Therapeutics PDX Granted Orphan Medicinal Product Designation by the European Commission
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
5. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
6. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
11. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2008)...tage A of Trial Assessing Regimen of Bavituxima..., TUSTIN, Calif., Oct. 7 /..., a clinical stage biopharmaceutical,company devel...ancer and,hepatitis C virus (HCV) infection, today... first stage of a Phase II trial of bavituximab in...
(Date:10/6/2008)...ollege of Gastroenterology Annual ...Newswire/ -- Combined results from two Phase 3,stu...terology Annual,Scientific Meeting (ACG) in Orland...igher healing rates than lansoprazole among patien...(EE). TAK-390MR combines,dexlansoprazole with a Du...
(Date:10/6/2008)...te to Improve Patient Safety, WASHINGTON, Oct. 6 ...,Cardiology in collaboration with the American Col...sociation today released consensus guidelines,outl... ulcers and,gastrointestinal (GI) bleeding among p... (NSAIDs) along with antiplatelet agents., Gastro...
(Date:10/6/2008).... 6 /- Complete,Genomics Inc., a newl...ng,company, and the Institute for Systems Biology ... populationwide human genome studies., In phase o...proprietary,DNA sequencing technology to sequence ...nce proof-of-concept has been demonstrated, ISB an...
Breaking Medicine Technology:Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 2Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 3Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 4Takeda's Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed 2Takeda's Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed 3Consensus Document Outlines Practical Steps for Reducing Gastrointestinal Risks of Antiplatelet and NSAID Use 2Consensus Document Outlines Practical Steps for Reducing Gastrointestinal Risks of Antiplatelet and NSAID Use 3Consensus Document Outlines Practical Steps for Reducing Gastrointestinal Risks of Antiplatelet and NSAID Use 4Complete Genomics and the Institute for Systems Biology Announce Partnership to Conduct the First Human Genome Population Study 2125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative 4101 1125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative 4101 2125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative 4101 3125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative 4101 4Pharmacopeia to Present at the 15TH Annual Future Leaders in the Biotech Industry Conference 4097 1Pharmacopeia to Present at the 15TH Annual Future Leaders in the Biotech Industry Conference 4097 2Pharmacopeia to Present at the 15TH Annual Future Leaders in the Biotech Industry Conference 4097 3Pharmacopeia to Present at the 15TH Annual Future Leaders in the Biotech Industry Conference 4097 4New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly 1567 1New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly 1567 2New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly 1567 3New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly 1567 4New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly 1567 5New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly 1567 6New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly 1567 7LUMEDX Updates Real Time Patient and Resource Scheduler for Healthcare Systems 4095 1LUMEDX Updates Real Time Patient and Resource Scheduler for Healthcare Systems 4095 2
... CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 18, 2007 -...ompany focused on,the discovery and development of... findings from its novel human-in-mouse (HIM) tiss...uccessfully created,invasive human tumors that dev...issue. This model enables scientists, for the firs...
...INESS WIRE)--Apr 19, 2007 - Antares Pharma, Inc.,(...tly completed,site application study demonstrating...mal gel, was absorbed on a bioequivalent,basis aft...in site,locations., The study was an open-label, c...harmacokinetic study. The trial enrolled 25,health...
Other Medicine Technology:Novel Human Tissue Transgenic Cancer Model May Offer Significant,Advance Toward Accurately Modeling Human Cancer 2Novel Human Tissue Transgenic Cancer Model May Offer Significant,Advance Toward Accurately Modeling Human Cancer 3Antares Pharma Announces Positive Results from Application Site,Study for Anturol 2Antares Pharma Announces Positive Results from Application Site,Study for Anturol 3
(Date:10/6/2008)... WASHINGTON, Oct. 6 /PRNewswire-USNewswire/ -- ...nst several companies alleging that they,submitted...kbacks and the,establishment of sham durable medic...nt announced today. The companies are McKesson Cor...MediNet), GGNSC Holdings LLC,Golden Gate Ancillar...
(Date:10/6/2008)... A study led by researchers at the University of ...that use of oral Vitamin D supplements bolsters pr...n the skin, and may help prevent skin infections t...most common form of eczema. , The study led by ...and chief of the Division of Dermatology at the UC...
(Date:10/6/2008)... SAN DIEGO, Oct. 6 /PRNewswire/ -- Developed in... of Pacific Palisades, CA is introducing,Revolutio...y into the,Plastic Surgery office of Dr. Steve Lav... XS-300(TM), is the first of its kind, and is base...hnology combined with,innovative proprietary softw...
(Date:10/6/2008)... Vision Audio Inc. has an...deo game designed to help train children with auti...Se Off-Road is a fun, non-violent learning experie...participate in their enhanced sound-based therapy,...dio ( http://www.easecd.com ). , ...
Breaking Medicine News(10 mins):Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Oral vitamin D may help prevent some skin infections 2Health News:Plan Your Breasts in 3-D 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 3
... the common cold remains as elusive as ever. A fed...the first drug aimed at treating the cause of the ...ed. In a unanimous decision, the Food and Drug Ad...l drugs said there were too many questions about t...
...hemists at the University of north Carolina at Ch... organisms convert genetic instructions into actio...unknown chemical site on a key enzyme that regulat...er known as RNA. When the chemical site is occupie...
...re right if they are feeling bombarded by commerci...ople instead of doctors tripled in the U.S. betwee...ertisements targeting consumers account for 15% of... up from almost 9% in 1996.// Spending that target...
...roup has petitioned the Food and Drug Administrati...Public Citizen says the drug, sold as Meridia, is ...diovascular causes such as heart attacks. But obes...ople died because of Meridia or because they were ...
Other Medicine News:
Since 1991 Intersurgical Incorporated manufactures high efficiency breathing filters, heat and moisture exchangers, ventilator circuits, oxygen therapy products, hand-held nebulizers and an extensive
...right product for any patient ranging from pediatr...nts with tracheotomies. These products offer super...l care applications., ,The Unti-Mist HME and HME/...d staff members. This entire product line of unti-...
Combination heat and moisture exchanger and bacterial/viral filters for Anesthesia and Respiratory applications.
Indications For Usage: ,Adult (recommended tidal volume >150ml), single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to
Medicine Products: